AbbVie (NASDAQ:ABBV) is basically a one-trick pony. The trick is an immunosuppressant called Humira, prescribed to fight rheumatoid arthritis and other conditions. It’s the best-selling drug in the world, bringing in $18.4 billion in 2017, but that might not be sufficient to support the future of AbbVie stock. While protected against direct competition in the U.S. until 2023, Humira is already facing biosimilars in Europe, as its protections there disappear.
For now, the good times roll on. AbbVie is due to report earnings Jan. 25, expecting sales of $8.36 billion for a 2018 total of $32.8 billion , 16% ahead of 2017’s $28.2 billion. Net income of $1.92 per share will bring that total to $6.92 per share for the year. But, as they say of both athletes and great beauties, Father Time is undefeated. AbbVie still faces a patent cliff, and growing opposition to rising prices. Nothing lasts forever. What works this year may not work next year. Know that before you buy AbbVie stock.
Source: InvestorPlace
Related Articles:
- 2 Low P/E Value-Stocks, Yielding 4% Or Higher
- 5 Stocks With A Low Debt To Total Capital
- Should You Sell A Dividend Stock After A Dividend Cut?
- All Investing Involves Risk
- 4 Dividend Stocks With Room To Increase Their Payout
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
REITs don’t just pay out attractive yields; many of these companies are terrific operators too. So not only do investors get to collect a so...
-
The company reported solid results for its fourth fiscal quarter. The business development company once again covered its dividend payout wi...
-
It’s in volatility like this that the value of dividends truly shines through. The market could be having a massive sell-off, but when a com...
-
If you are interested in high-yield dividend stocks, it’s better to focus on a company’s history of growing its dividend rather than just lo...
-
When the average S&P 500 company pays less than two percent, a 6.5%-yielding stock certainly deserves income investors’ attention. A Top...
-
While conventional wisdom holds that you reach for yield, my strategy has been to look first for capital gains, then to management teams tha...
-
Buying and holding high-quality dividend stocks is arguably the best way for investors to predictably achieve outsized returns over the long...
-
I screened for cheap dividend stocks that are showing some upward movement, trading above their 50-day moving average, with a 3% or higher d...
-
There are hundreds of high-yield dividend stocks on the market. At least, that's the case if your definition of high dividend yield isn&...
-
If you are a longtime yield seeker, you’ve probably noticed one thing: most of the double-digit yielders also happen to be beaten-down stock...
0 comments
Post a Comment
Post a Comment